Denali Therapeutics Inc. (DNLI)
Nasdaq: DNLI · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2017
Filings
275 filings since 2017 beside 514 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 34 days after the quarter ended. The proxy statement was last filed Apr 21, 2026.
Filings a yearinsider forms included
757910577971177054
2026 counts to Nov 13, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jul 28, 2026
8-K items 2.01, 9.01
Purchase or sale of a business completed · Current report
Jul 27, 2026
Jun 18, 2026
8-K items 1.01, 7.01, 9.01
Major agreement signed; Investor disclosure (Regulation FD) · Current report
Jun 12, 2026
Mar 31, 2026
8-K items 2.03, 7.01
New debt or obligation taken on; Investor disclosure (Regulation FD) · Current report
Mar 27, 2026
Dec 10, 2025
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Dec 9, 2025
Dec 4, 2025
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
40 of 275 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.